 |
|
Fatty Acid and Vitamin D Status in the EPIC Trials of Crohn Disease Treatment
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: The study of treatment of Crohn disease by Dr Feagan and colleagues1 is important because smaller clinical trials are more susceptible to bias, are often less methodologically rigorous, and produce relatively less precise estimates of the true effect of treatment than large multicenter studies. However, the methodology of this study overlooked 2 potential sources of type II error.
First, no measurements were made of essential fatty acid status at the start or end of the trial. It is not possible to assess the quality of the randomization for either the baseline omega-3 status, the baseline intake of the proinflammatory omega-6 fatty acids, or the baseline ratios of omega-6 to omega-3. Additionally, the quality of the intervention cannot be assessed, including omega-3 fatty acid absorption in these patients or their actual adherence to the protocol.
Second, no measurements were made of the vitamin D status in this population. . . . [Full Text of this Article]
Gregory A. Plotnikoff, MD, MTS
gregory.plotnikoff@allina.com
Institute for Health and Healing
Abbott Northwestern Hospital
Minneapolis, Minnesota
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease: The EPIC Randomized Controlled Trials
, , , , , , , , , , , , , , , , , , , , , , , , and
JAMA. ;299():1690-1697.
FULL TEXT
RELATED LETTER
Fatty Acid and Vitamin D Status in the EPIC Trials of Crohn Disease Treatment--Reply
JAMA. ;300():650-650.
FULL TEXT
|
